https://de.marketscreener.com/kurs/aktie/HUTCHMED-CHINA-LIMITED-59660104/news/HUTCHMED-erhalt-Complete-Response-Letter-der-U-S-FDA-fur-Surufatinib-zur-Behandlung-von-fortgesch-40282781/?utm_source=telegram&utm_medium=social&utm_campaign=share